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Purpose: Genome-wide association studies and targeted sequencing studies of candidate genes have
identiﬁed common and rare variants that are associated with age-related macular degeneration (AMD). Whole-
exome sequencing (WES) studies allow a more comprehensive analysis of rare coding variants across all
genes of the genome and will contribute to a better understanding of the underlying disease mechanisms. To
date, the number of WES studies in AMD case-control cohorts remains scarce and sample sizes are limited. To
scrutinize the role of rare protein-altering variants in AMD cause, we performed the largest WES study in AMD to
date in a large European cohort consisting of 1125 AMD patients and 1361 control participants.
Design: Genome-wide case-control association study of WES data.
Participants: One thousand one hundred twenty-ﬁve AMD patients and 1361 control participants.
Methods: A single variant association test of WES data was performed to detect variants that are associated
individuallywithAMD.Thecumulativeeffectofmultiple rarevariantswith1genewasanalyzedusingagene-basedCMC
burden test. Immunohistochemistry was performed to determine the localization of the Col8a1 protein in mouse eyes.
Main Outcome Measures: Genetic variants associated with AMD.
Results: We detected signiﬁcantly more rare protein-altering variants in the COL8A1 gene in patients (22/
2250 alleles [1.0%]) than in control participants (11/2722 alleles [0.4%]; P ¼ 7.0710e5). The association of rare
variants in the COL8A1 gene is independent of the common intergenic variant (rs140647181) near the COL8A1
gene previously associated with AMD. We demonstrated that the Col8a1 protein localizes at Bruch’s membrane.
Conclusions: This study supported a role for protein-altering variants in the COL8A1 gene in AMD patho-
genesis. We demonstrated the presence of Col8a1 in Bruch’s membrane, further supporting the role of COL8A1
variants in AMD pathogenesis. Protein-altering variants in COL8A1 may alter the integrity of Bruch’s membrane,
contributing to the accumulation of drusen and the development of AMD. Ophthalmology 2018;-:1e11 ª 2018 by
the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Supplemental material available at www.aaojournal.org.
Age-related macular degeneration (AMD) is the leading Geographic atrophy (GA), also referred to as the dry form
cause of irreversible vision loss among persons older than
50 years in the developed world.1,2 The disease is charac-
terized by progressive damage to the retinal pigment
epithelium and photoreceptors in the macula, ultimately
leading to visual impairment and blindness. In the early
stages of AMD, a spectrum of changes occur, including
hypopigmentations and hyperpigmentations of the retina
and the formation of extracellular deposits (drusen) in
Bruch’s membrane.2 These drusen increase in size and
number during the intermediate stages. Two types of
AMD can develop in the end stage of the disease.ª 2018 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.of AMD, is characterized by retinal pigment epithelium
cell atrophy, causing photoreceptor cell death. Choroidal
neovascularization (CNV), also called the wet form of
AMD, is characterized by the formation of new blood
vessels, leading to leakage, hemorrhages, and sudden loss
of vision.
Age-related macular degeneration is a multifactorial
disease inﬂuenced by a variety of environmental factors,
including age, smoking history, and sunlight exposure
during working life.3,4 There is a large genetic component to
the cause of AMD, with an estimated heritability between1https://doi.org/10.1016/j.ophtha.2018.03.040
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Ophthalmology Volume -, Number -, Month 201846% to 71%.5 Initially, genetic studies in AMD mainly
focused on common variants in the population through
genome-wide association studies (GWAS) using single
nucleotide polymorphism (SNP) microarrays.6e9 These
studies identiﬁed genetic variants in or near genes belonging
to 4 main pathways, including the complement system, li-
poprotein metabolism, angiogenesis, and extracellular ma-
trix remodeling. However, most common genetic variants
identiﬁed by GWAS are located in noncoding or intergenic
regions, and subsequently it is not always apparent which
gene near the top-associated SNP is the causative gene.
Involvement of genes in a disease can be established
further by identiﬁcation of protein-altering variants in the
coding regions, which often are rare in the population.8
Thus, several studies focused on the discovery of rare
variants by sequencing genes in AMD loci. In these
studies, rare variants were identiﬁed in complement factor
H (CFH), complement factor I (CFI), complement C3, and
complement C910e14 that are associated individually with
AMD. Recently, a GWAS performed by the International
AMD Genomics Consortium using an exome array enriched
with rare variants identiﬁed 52 AMD-associated variants at
34 genomic loci. Of these 52 variants, 7 variants were rare
and 45 variants were common.8
Testing the association of individual rare variants can be
challenging, because very large sample sizes are needed to
obtain sufﬁcient power.15 Instead of testing each variant
individually, gene-based burden tests can evaluate the cu-
mulative effects of multiple genetic variants within a gene,
leading to an increased study power.16 Sequence analysis of
the coding regions of 681 genes within AMD-associated
loci in 1676 AMD patients and 745 control participants
identiﬁed a higher burden of rare variants in CFI in patients
(7.8%) than in control participants (2.3%).12,17,18 Further-
more, evaluation of the cumulative effect of rare protein-
altering variants, using exome array data by the International
AMD Genomics Consortium, identiﬁed a signiﬁcant burden
in 4 AMD-associated genes: CFH, CFI, tissue inhibitor of
metalloproteinases 3 (TIMP3), and solute carrier family 16
member 8 (SLC16A8).8 A limitation of these studies is that
either rare variants in a limited set of genes12 or a limited
number of rare variants across the genome8 were tested.
Whole-exome sequencing (WES) studies allow a more
comprehensive analysis of rare protein-altering variants
across all genes of the genome.19 To date, the number ofWES
studies in AMD case-control cohorts remain few and sample
sizes are limited. Whole-exome sequencing of 213 neo-
vascular AMD patients and 1553 healthy control participants
from East Asian populations showed association of a variant
in ubiquitin protein ligase E3D (UBE3D) with AMD.20 More
recently, WES of 39 individuals with bilateral CNV with low
genetic risk scores and 36 unaffected control participants with
high genetic risk did not detect any genes that reached
genome-wide signiﬁcance.21
The main goal of the present study was the identiﬁcation
of rare protein-altering variants that are associated with
AMD. To achieve this goal, we performed WES in a large
European cohort consisting of 1125 patients and 1361
control participants to scrutinize the role of coding variants
across the human genome in the cause of AMD.2Methods
Study Population
A cohort of 2516 individuals of European ancestry (1493 women
and 1023 men with a mean age of 79 years) was recruited from the
European Genetic Database (www.eugenda.org; n ¼ 799) and the
Rotterdam Study (n¼ 1717). From the European Genetic Database,
667 AMD patients (488 patients with late AMD) and 132 healthy
control participants were evaluated for this study. Inclusion of in-
dividuals took place between December 2005 and June 2014. All
participants underwent clinical evaluation by a retinal specialist and
were graded for AMD according to the Cologne Image Reading
Center protocol.22 Fundus photographs and spectral-domain OCT
images were used to classify AMD by the presence of pigmentary
changes together with at least 10 small drusen (<63-mmdiameter) or
the presence of intermediate drusen (63e124-mm diameter) or large
drusen (125-mm diameter) in the Early Treatment Diabetic Reti-
nopathy Study grid. Furthermore, late AMD was deﬁned as either
AMD with subfoveal GA or CNV in at least 1 eye. Control
individuals were included in the study when they exhibited no signs
of AMD in either eye and were at least 65 years of age at inclusion.
The design of the Rotterdam Study has been described previously
in detail.23,24 This prospective, population-based follow-up study
started in 1990 and has follow-up visits every 5 years. For this
analysis, we included a total of 466 AMD patients (74 patients with
late AMD) and 1269 control participants from the Rotterdam Study I
subcohort 55 years of age and older with WES data. All participants
underwent fundus photography of themacula using a 35 ﬁlm fundus
camera (Topcon TRV-50VT; Topcon Global Gateway, Tokyo,
Japan) after pupillary dilation. For the last 2 follow-up visits, a
Topcon digital 35 color fundus camera (Topcon TRC 50EX; with a
Sony DXC-950P 0.44 megapixel digital camera; Sony Corporation,
Minato, Japan)was used. Fundus photographswere graded according
to the Rotterdam Classiﬁcation, which is based on the Wisconsin
Age-Related Maculopathy Grading System25 and the modiﬁed
International Classiﬁcation System.26 Patients were participants
with early or late AMD, which is at least soft distinct drusen
(63-mm diameter), in combination with hypopigmentary or
hyperpigmentary changes or soft indistinct drusen (125-mm
diameter) or reticular drusen. Control participants were those older
than 65 years with no signs of AMD or those older than 75 years of
age with hard or soft distinct drusen (63-mm diameter) or
pigmentary abnormalities.
In both cohorts, both eyes of all participants were graded
separately by experienced graders (T.S.), who were under the su-
pervision of senior retinal specialists (P.T.V.M.dJ., J.R.V.,
C.C.W.K., and S.F.). The worst affected eye was used to classify
the individual. Written informed consent was obtained from all
participants. The study was approved by the local ethics commit-
tees on research involving human subjects of the participating
centers, and all procedures were conducted according to the tenets
of the Declaration of Helsinki. The Rotterdam Study was approved
by the Medical Ethics Committee of the Erasmus Medical Center
and by the Ministry of Health, Welfare and Sport of The
Netherlands, implementing the Wet Bevolkingsonderzoek: ERGO
(Population Studies Act: Rotterdam Study).
Whole-Exome Sequencing Capture and Variant
Calling
Genomic DNA of all participants was isolated from blood samples
according to standard procedures. DNA was fragmented into 200-
to 400-bp fragments, and the exome library was prepared on a
Caliper Sciclone NGS workstation (Caliper Life Science, Hop-
kinton, MA). The exome was captured with the Nimblegen
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Madison, WI), covering 329 028 exons and 710 miRNAs. Paired-
end sequencing was performed on 2 Illumina HiSeq2000 se-
quencers using Illumina TruSeq V3 chemistry (Illumina, Inc, San
Diego, CA). High-quality reads were mapped to the UCSC hg19
reference genome using the Burrows-Wheeler alignment tool.27
Variant calling was performed by Genome Analysis ToolKit
(GATK) HaplotypeCaller, following the GATK best practice
guidelines (available at https://software.broadinstitute.org/gatk;
accessed July 2016). Single nucleotide variants and indels were
ﬁltered separately using GATKs Variant-Quality Score Recali-
bration module. Variants with a variant quality score log-odds
(VQSLOD) score lower than e7.2 were removed. Variant anno-
tation was done using annotate variation (ANNOVAR)28 and an
in-house pipeline developed by the Department of Human Ge-
netics of the Radboud University Medical Center.29 Functional
effects of variants were predicted by 3 different prediction
algorithms: Sorting Tolerant From Intolerant (SIFT),30 PolyPhen-
2,31 and Combined Annotation Dependent Depletion (CADD)32
(threshold of deleteriousness for CADD, 20). In addition,
conservation of candidate variants was estimated by PhyloP
(threshold for deleteriousness, 2.7) and Grantham (threshold
for deleteriousness, 80).
Data Quality Control
Stringent quality control steps were performed with PLINK version
1.0733 to exclude those positions that had high chances of being false
positive results. Variants were removed according to the following
criteria: (1) genotypes with a missing rate of more than 5% of
individuals and (2) common variants (minor allele frequency,
>0.05) that were not in Hardy-Weinberg equilibrium in control
participants. After these quality control steps, a total of 744 022
variants were available for analysis. Subject-level quality control
was carried out, excluding individuals with a call rate of less than
95%or an extreme inbreeding coefﬁcient (cutoff,0.12).34 Pairwise
identity by descent was calculated to conﬁrm the lack of relatedness
among all samples (PI-HAT, <0.25). A multidimensional scaling
was performed with PLINK version 1.07 to obtain the principal
components, which were used to conﬁrm that all individuals were
clustered as European samples and to correct for population
stratiﬁcation (Fig S1, available at www.aaojournal.org). After all
quality controls, a cohort of 1125 AMD patients and 1361 control
participants was selected for association analyses.
Statistical Analyses
A single variant association test was carried out with RARE-
METALWORKER (available at http://genome.sph.umich.edu/
wiki/RAREMETALWORKER; accessed January 2017) using a
linear mixed model. This software performs a score statistics-based
rare-variant association analysis, providing single-variant results
and a varianceecovariance matrix. Linkage disequilibrium
relationships between markers within 1 Mb are stored in the
covariance matrix to perform the gene-level analyses. Analysis was
performed using an additive model controlling for age, gender,
clinic, and the ﬁrst 4 components. Genome-wide signiﬁcance levels
used for single-variant analysis were deﬁned based on Bonferroni
correction (P  510e8).
By deﬁnition, single-variant analyses have limited power to
detect rare variant associations, especially for limited sample sizes.
Association power was increased by evaluating the accumulated
association of multiple rare exonic variants within each gene.35
Gene-based burden tests were carried out by RAREMETAL36
using the summary statistics and linkage disequilibrium matrices
generated in the single-variant analysis. Three different methodswere used: the Combined Multivariate and Collapsing (CMC)_
counts and Variable Thresholds tests, which are burden tests that
assume all alleles to inﬂuence the association in the same direction,
and the sequence kernel association test (SKAT) test, which
evaluates risk and protective alleles to maximize power. A subset
of 308 784 rare protein-altering variants (minor allele frequency,
<0.05) were used in the analysis to avoid the major presence of
noneprotein-altering variants (n ¼ 435 238) diluting the burden
because of deleterious variants. We selected rare variants that alter
amino acid residues (nonsynonymous variants), truncate proteins
(nonsense and stop-gain variants), or affect RNA splicing (variants
affecting the invariate splice donor and splice acceptor sites).
First, we focused on the 34 previously reported AMD loci and
we applied a Bonferroni-corrected signiﬁcance threshold based on
the 619 genes located within 500 kb of the top-associated SNP in
each of the AMD loci (according to ref.8) and carrying at least 1
rare protein-altering variant (P < 0.05/619 ¼ 8.0710e5). Hap-
loview37 was used to reconstruct the region of interest to validate
that the rare Collagen Type VIII Alpha 1 Chain (COL8A1)
variants belong to different haplotype blocks than the common
risk variant rs140647181 identiﬁed in a previous single-variant
test.8 In a secondary analysis, we extended the search of rare
variant burden to all genes across the genome, applying a
Bonferroni-corrected signiﬁcance threshold of 0.05/17 596 ¼
2.8410e6. Quantile-quantile plots of P values from single-variant
analysis and gene-based tests were generated to discard any batch
effect or population substructure.
Characterization of Phenotypic Features of
COL8A1 Variant Carriers
Phenotypic characterization was performed including participants
from the Rotterdam Study. Age-related macular degeneration fea-
tures were based on the eye with the most severe phenotype.
Glaucoma-related features were the mean of both eyes at the last visit
during follow-up. Refraction was based on the mean spherical
equivalent of both eyes at the last visit during follow-up, or the last
visit before cataract extraction. Statistical signiﬁcancewas testedwith
an independent sample t test for continuous variables, a chi-square or
Fisher exact test for dichotomous variables, and a ManneWhitneyU
test for drusen area because of its nonnormal distribution. All tests
performed were 2-sided.
Mouse Retina Staining
Eyes from P60 C57BL/6J wild-type mice were enucleated and
embedded in Tissue-Tek O.C.T. Compound (4583, Sakura Finetek,
Alphen aan den Rijn, the Netherlands). Seven-micrometer sections
were dried for 1 hour at room temperature. Using the hydrophobic
PAP pen (Z377821-1EA, Sigma-Aldrich, St. Louis, MO), a circle
was drawn surrounding the sections. Retinas then were incubated for
20 minutes in phosphate-buffered saline (PBS) 0.05% Tween
(8.22184.0500, Merk millipore, Burlington, MA) and 0.05% Triton
X-100 (9002-93-1, Sigma-Aldrich, St. Louis, MO) at room tem-
perature. After blocking in 0.1% ovo albumin (A4344,0250,
AppliChem GmbH, Darmstadt, Germany), 0.5% ﬁsh gelatin
(G7041-100G, Sigma-Aldrich, St. Louis, MO), and 5% bovine
serum albumin (A7906-100G, Sigma-Aldrich, St. Louis, MO) in
PBS for 30 minutes, primary antibodies were added and incubated
overnight at 4 C. Primary antibodies used included rabbit poly-
clonal anticollagen type VIII a 1 (1:50; HPA053107, Sigma-
Aldrich, St. Louis, MO) and rat monoclonal Laminin b-1 (1:50;
MA5-14657, ThermoFisher Scientiﬁc,Waltham,MA). Retinaswere
washed 45 minutes in PBS and incubated with the goat antirabbit
Alexa 568 (1:500; A11006, Life Technologies, Carlsbad, CA) and
goat antirat Alexa 488 secondary antibody (1:500; A11006, Life3
Figure 1. Gene-based burden test for rare variants using whole-exome
sequencing data of 1125 age-related macular degeneration (AMD) pa-
tients and 1361 control participants of European ancestry. The blue line
indicates the signiﬁcance threshold (P < 0.05/619 ¼ 8.0710e5) for
testing 619 genes located in or near AMD-associated loci. The COL8A1
gene reaches the signiﬁcance threshold and is depicted in blue. The red line
indicates the genome-wide signiﬁcant threshold (P < 0.05/17 596 ¼
2.8410e6) for genes outside the AMD-associated loci. The KBTBD12
and ZNF787 genes do not reach genome-wide signiﬁcance and are depicted
in red. Bonferroni correction was applied to both signiﬁcance thresholds.
Figure 2. Haploblock structure of the genomic region encompassing the
COL8A1 gene and the age-related macular degeneration-associated com-
mon intergenic variant rs140647181. A Haploview plot was generated
based on common single nucleotide variants extracted from the 1000
Genomes phase 3 dataset. Red triangles marked with black lines represent
genomic regions that are closely linked and are inherited together. This
haplotype block distribution shows that the rare protein-altering variants
identiﬁed in the COL8A1 gene (indicated with an asterisk) are not located
in the same haplotype block as rs140647181, meaning that the rare variants
are not inherited together with the common intergenic variant. This
supports that the rare variant burden in COL8A1 is independent of the
common intergenic variant rs140647181.
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(dilution, 1:500 in blocking solution). Nuclei staining with 4,06-
diamidino-2-phenylindole (1:8000; 0100-20, I.T.K Diagnostics
B.V, Uithoorn, the Netherlands) was combined with the secondary
antibody incubation. Sections then were washed 45 minutes in
PBS, rinsed in MilliQ-puriﬁed water, and mounted in Prolong Gold
antifade reagent (P36930, Life Technologies, Carlsbad, CA). Im-
aging was performed using a Zeiss Z1 Imager. All images were
obtained at the same intensity. An image with ZEN software was
created to obtain TIFF or JPEG ﬁles.Results
Whole-Exome Sequencing
We performed WES on 2516 unrelated individuals (1125 patients
and 1361 control participants), obtaining an average of 2.8 billion
bases per individual and a mean coverage of 63. After variant
calling and recalibration, a total of 759 450 variants were identiﬁed,
being 754 503 single nucleotide variants and 4947 insertions or
deletions (indels). Of the complete set of variants, 7.6% (n¼ 57 571)
were common variants, and the remaining 92.4% (n¼ 701 879) were
classiﬁed as rare variants with a minor allele frequency of less than
0.05. Genotype data obtained from WES were checked for concor-
dancewith the genotype data of a customized Illumina exome array,8
available for a subset of the study population (n ¼ 1330). Variants
genotyped by both WES and exome array (n ¼ 80 779) had a
concordance rate of more than 99%, demonstrating the high
quality of our sequencing data and the high accuracy of our
genotype calling.
Single Variant and Gene-Based Association
Analyses
We ﬁrst performed a genome-wide single-variant association anal-
ysis for individual common and rare variants using the WES data of
1125 AMD patients and 1361 control participants of European
ancestry. Results conﬁrmed association of variants in the CFH and
Age-Related Maculopathy Susceptibility 2 (ARMS2) genes with4AMD in this cohort.8 Two common coding variants in CFH
(rs1061170 [P ¼ 4.2410e11] and rs1061147 [P ¼ 3.3010e10])
and 1 common variant in ARMS2 (rs10490924 [P ¼ 1.8910e9])
were associated with AMD above the threshold of genome-wide
signiﬁcance (P  510e8; see Figs S2 and S3, available at
www.aaojournal.org).
Subsequently, we evaluated the burden of rare protein-altering
variants in genes at previously identiﬁed AMD loci using gene-
based burden tests. For this analysis, 619 genes were selected
that are within 500 kb of the top-associated SNP at 34 AMD loci
identiﬁed in a recent GWAS8 (Table S1, available at
www.aaojournal.org). A CMC burden test (applying genomic
control l ¼ 0.940) showed a signiﬁcant burden of rare variants
in the COL8A1 gene (P ¼ 7.0710e5; Fig 1).
We then expanded the burden analysis to protein-altering variants
across the genome. The CMC burden test (applying genomic control
l ¼ 1.057) showed a suggestive association in the KBTBD12
(P ¼ 3.5010e6) and ZNF787 (P ¼ 2.8910e5) genes, but these
associations did not reach the genome-wide signiﬁcance level (Fig 1).
The signal at the KBTBD12 gene did reach the genome-wide signif-
icance threshold when the SKAT test was applied (P ¼ 4.4510e7).
In both tests, the association signalwas drivenmainly by the effect of 1
rare variant (rs148151101; P¼ 1.5210e6). However, this particular
variant inKBTBD12was not associated with AMD in an exome array
analysis in a cohort of 16 144 AMD patients and 17 832 control
participants of European ancestry by the International AMD Geno-
mics Consortium (P ¼ 0.387).8
Rare Variant Burden in the COL8A1 Gene
We next determined whether the rare variant burden in COL8A1 is
independent of the previously identiﬁed AMD-associated common
variant (rs140647181) near the COL8A1 gene.8 This common
variant is intergenic, located 560 kb downstream of DCBLD2
and 177 kb upstream of COL8A1. To evaluate the independence
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genic variant rs140647181, we reconstructed the haplotype block
structure at the COL8A1 locus to visualize which regions of the
gene are linked closely and are inherited together. Several
recombination events between the rare protein-altering variants in
the COL8A1 gene and rs140647181 were observed, meaning that
the region containing the rare variants is not inherited together with
the region containing the common intergenic variant (Fig 2). These
results support that the rare variant burden observed in this study is
independent of the common intergenic variant previously
associated with AMD.
The COL8A1 burden is explained by 14 rare protein-altering var-
iants spread across the protein (Fig 3), which are found more often in
patients (22/2250 alleles [1.0%]) than in control participants (11/2722
alleles [0.4%]; Table 1; Table S2, available at www.aaojournal.org).
Six variants, including 1 nonsense variant (p.G414*) and 5 missense
variants (p.M70T, p.A96V, p.E520K, p.G711E, and p.M744I), were
identiﬁed only in patients, but not in control participants, and 5
additional variants (p.R225Q, p.A250V, p.R362Q, p.G695D, and
p.L741F) were found at a higher frequency in patients than in
control participants. The nonsense variant p.G414* is predicted to
lead to a premature termination in the COL1 domain, or may cause
nonsense-mediated decay of the COL8A1 mRNA. Two missense
variants (p.G695D and p.G711E) are predicted to be deleterious with
all conservation and pathogenicity tests used and have a CADD score
of 20 or more, which classiﬁes them among the top 0.75% most
deleterious mutations that are found in the human genome (Table 1).
The 2 missense variants p.G695D and p.G711E affect 2 highly
conserved aminoacid residues in thenoncollagenous1domain (Fig3).
Phenotypic Features of COL8A1 Variant Carriers
We examined the effect of the COL8A1 variants on the AMD
phenotype in participants from the Rotterdam Study only, becauseFigure 3. Location and conservation of protein-coding variants in COL8A1. A
degeneration (AMD) patients and control participants in the different COL8A1
and noncollagenous domain 2 (NC2). Variants detected only in control indivi
different species. Boxed missense variants identiﬁed in AMD patients, predicted
highly conserved glycine residues in the NC1 domain.it is a population-based cohort study without prior selection on
phenotype. This group consists of 16 AMD patients carrying a
COL8A1 variant, 11 individuals carrying a COL8A1 variant
without AMD, and 450 AMD patients without a COL8A1 variant
(Table 2). Features of early AMD were not signiﬁcantly different
between COL8A1 carriers and noncarriers with AMD, although
COL8A1 carriers had a somewhat higher proportion of
hyperpigmentary changes (P ¼ 0.062). No statistically signiﬁcant
differences were found for glaucoma-related features such as
intraocular pressure and vertical cup-to-disc ratio. The groups
differed signiﬁcantly in spherical equivalent, with COL8A1 carriers
being more myopic (P ¼ 0.005). However, there was no signiﬁcant
difference in the proportion of participants with mild and severe
myopia.
Localization of COL8A1 to Bruch’s Membrane
Localization of COL8A1 in the retina has not yet been described in
the literature. To assess whether COL8A1 is localized at Bruch’s
membrane, the main AMD disease site, we performed immuno-
histochemistry on retinas of wild-type C57BL/6J adult mice. Mice
were selected for these experiments because mouse and human
retinas exhibit a common basic architecture38 and often are used to
model human retinal disease, although mice lack a macula and
have a higher photoreceptor cell density and a relatively thicker
Bruch’s membrane in the central retina.39 Laminin b-1 was used
as a marker for Bruch’s membrane.40 The coimmunostaining of
Laminin b-1 and Col8a1 robustly demonstrated that both
proteins localize at Bruch’s membrane (Fig 4). In addition,
Col8a1 showed some expression in the photoreceptor layer,
being most evident at the outer plexiform layer, the synaptic
region between the photoreceptor cells, and the inner nuclear
layer cells. To exclude that the staining was the result of
background staining derived from the use of secondary, Location of rare protein-altering variants identiﬁed in age-related macular
domains: triple-helical region (COL1), noncollagenous domain 1 (NC1),
duals are depicted in gray. B, Alignment of COL8A1 protein sequences of
to be deleterious in all conservation and pathogenicity tests (Table 1), affect
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Table 1. Rare Protein-Altering Variants Identiﬁed in the COL8A1 Gene in 1125 Age-Related Macular Degeneration Patients and 1361 Controls
Protein
Change
cDNA
Change Domain PhyloP* Grantham*
SIFT
(Score)*
PolyPhen2
(Score)* CADD*
Counts
Patients
(n [ 2250)
Counts
Controls
(n [ 2722)
Single-Variant
P Value
Single-Variant
Odds Ratio
(95% Conﬁdence
Interval)
Burden
Test
P Value
Burden Test
Odds Ratio (95%
Conﬁdence Interval)
V58A 173T/C NC2 4.317 64 Damaging
(0.014)
Poss. damaging
(0.646)
19.7 0 1 0.56 0.78232 (0.34e1.79) 7.07 
10e5
1.34153 (1.16e1.55)
M70T 209T/C NC2 4.216 81 Damaging
(0.004)
Benign (0.001) 22.5 1 0 0.11 1.9552 (0.85e4.47)
A96V 287C/T NC2 1.266 64 Tolerated
(1)
Benign (0) 5.6 1 0 0.06 2.18674 (0.96e5)
P193R 578C/G COL1 4.028 103 Damaging
(0.02)
Poss. damaging
(0.463)
22.1 0 1 0.61 0.80691 (0.35e1.84)
R225Q 674G/A COL1 6.782 43 Tolerated
(0.328)
Benign (0.008) 22.9 1 1 0.48 1.23339 (0.69e2.21)
A250V 749C/T COL1 2.257 64 Tolerated
(0.338)
Benign (0) 2.5 1 1 0.83 0.93868 (0.52e1.68)
R362Q 1085G/A COL1 3.041 43 Tolerated
(0.105)
Benign (0.071) 20.5 6 3 0.06 1.3026 (0.99e1.72)
G414* 1240G/T COL1 9.803 NA NA NA 39 2 0 0.01 2.14633 (1.20e3.85)
E520K 1558G/A COL1 9.828 56 Tolerated
(0.296)
Poss. damaging
(0.945)
21.6 1 0 0.82 1.1015 (0.48e2.52)
H668Q 2004C/G NC1 2.728 24 Damaging
(0.004)
Prob. damaging
(0.989)
25.9 0 1 0.45 0.72856 (0.32e1.66)
G695D 2084G/A NC1 9.873 94 Damaging
(0.005)
Prob. damaging
(0.977)
26.7 4 2 0.08 1.3489 (0.96e1.89)
G711E 2132G/A NC1 9.873 98 Damaging
(0.014)
Prob. damaging
(1)
26.7 1 0 0.08 2.1159 (0.92e4.84)
L741F 2223G/T NC1 0.615 22 Tolerated
(0.084)
Benign (0.366) 22.2 2 1 0.11 1.47754 (0.92e2.38)
M744I 2232G/C NC1 9.477 10 Tolerated
(0.186)
Benign (0.001) 24.8 2 0 0.13 1.56374 (0.87e2.81)
COL1 ¼ triple-helical region; NA ¼ not applicable; NC1 ¼ noncollagenous domain 1; NC2 ¼ noncollagenous domain 2; Poss. ¼ possibly; Prob. ¼ probably; Sift ¼ Sorting Tolerant From Intolerant;
CADD ¼ Combined Annotation Dependent Depletion.
*Thresholds for deleteriousness: PhyloP  2.7, Grantham  80, SIFT  0.1, PolyPhen  0.4, and CADD  20.
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Table 2. Comparison of Phenotypic Features between Carriers and Noncarriers of COL8A1 Variants in the Rotterdam Study
Protein Change
COL8A1 Variant and
Age-Related Macular
Degeneration (n [ 16)
COL8A1 Variant, No Age-Related
Macular Degeneration
(n [ 11)
No COL8A1 Variant
and Age-Related Macular
Degeneration (n [ 450)
Age at last visit (yrs) 79.6 (SD, 6.3) 82.5 (SD, 7.9) 80.0 (SD, 6.5)
Spherical equivalent e0.37 (SD, 1.86)* 1.14 (SD, 1.83) 1.26 (SD, 2.29)*
Mild myopia (e3 to e6 D; %) 3/16 (19) 1/11 (9) 23/437 (5)
Severe myopia ( e6 D; %) 0/16 (0) 0/11 (0) 2/437 (0)
Corneal curvature (mm) 7.72 (SD, 0.32) 7.58 (SD, 0.26) 7.70 (SD, 0.26)
IOP (mmHg) 13.8 (SD, 3.0) 14.3 (SD, 2.8) 13.9 (SD, 3.3)
VCDR 0.36 (SD, 0.18) 0.37 (SD, 0.24) 0.32 (SD, 0.18)
Subtype of AMD (no.) 3 GA, 0 CNV, 0 mixedy, 13 early d 29 GA, 21 CNV, 21 mixedy, 379 early
Drusen area >10% (%) 4/16 (25) 0/11 (0) 88/450 (20)
Presence of hyperpigmentation (%) 14/16 (88) 1/11 (9) 287/450 (64)
Presence of reticular drusen (%) 0/16 (0) 0/11 (0) 27/450 (6)
Presence of drusen outside grid (%) 10/16 (63) 7/11 (64) Not available
AMD ¼ age-related macular degeneration; CNV ¼ choroidal neovascularization (wet AMD); D ¼ diopters; GA ¼ geographic atrophy (dry AMD); IOP ¼
intraocular pressure; SD ¼ standard deviation; VCDR ¼ vertical cup-to-disc ratio.
*P ¼ 0.005 independent samples t test (2-tailed) between AMD patients carrying a COL8A1 variant (n ¼ 16) and AMD patients without variants in
COL8A1 (n ¼ 437), t ¼ 2.81, degrees of freedom, 451.
yGeographic atrophy and CNV.
Corominas et al  WES in AMD Identiﬁes Variants in COL8A1antibodies, we performed the same procedure without adding
primary antibody (Fig S4, available at www.aaojournal.org). This
conﬁrmed that the Col8a1 and Laminin b-1 staining observed at
Bruch’s membrane is the result of the primary antibody.Discussion
In this study, we aimed to scrutinize the role of rare protein-
altering variants in the cause of AMD using WES. By
focusing on rare protein-altering variants in the coding
regions, we sought to determine the causality of genes in the
disease. Because most top SNPs identiﬁed in GWAS studies
for AMD are in noncoding or intergenic regions,8 it is not
always apparent which gene near the top-associated SNP
is the causative gene. In this study, WES analysis in 1125
AMD patients and 1361 control participants revealed a
signiﬁcant burden of rare protein-altering variants in the
COL8A1 gene in AMD. The COL8A1 burden is explained
by 14 rare protein-altering variants spread across the protein,
which are found more often in patients (22/2250 alleles
[1.0%]) than in control participants (11/2722 alleles [0.4%]).
The association of rare variants in the COL8A1 gene is
independent of the common AMD-associated intergenic
variant rs140647181, located 560 kb downstream of
DCBLD2 and 177 kb upstream of COL8A1.8 No rare-variant
burden was observed in the DCBLD2 gene, nor in other
genes at the same AMD locus. Taken together, these ﬁnd-
ings support that the previously observed association of the
common intergenic variant rs140647181 is driven by effects
on COL8A1 rather than by other genes at the locus.
COL8A1 encodes 1 of the 2 a chains of collagen type VIII,
which is a major component of ocular basement mem-
branes.41 Several studies have investigated the association
between alterations in genes encoding the 2 subunits of
collagen VIII (COL8A1 and COL8A2) and ocularabnormalities such as myopic CNV, anterior segment
dysgenesis, and thin corneal stroma.42e45 Although several
studies postulated a role for COL8A1 in ocular basement
membranes, so far no published data conﬁrm the localization
of COL8A1 in Bruch’s membrane. There are several lines of
evidence to support that Bruch’s membrane plays a crucial
role in AMD. Because of its location, Bruch’s membrane is
involved intensively in the exchange of numerous bio-
molecules, nutrients, and waste products between the retinal
pigment epithelium and the choroidal capillary bed.46 A
disturbed integrity or stability of Bruch’s membrane can
lead to accumulation of these products in drusen or can
weaken the physical barrier against the invasion of new
blood vessels into the retina.47 In this study, we
demonstrate the presence of Col8a1 in Bruch’s membrane,
further supporting the role of COL8A1 variants in AMD
pathogenesis.48
Protein-altering variants in COL8A1may lead to structural
alterations in Bruch’smembrane, which can be responsible for
the development of AMD.43 Interestingly, we describe 14 rare
protein-altering variants in COL8A1, including 1 nonsense
variant (p.G414*) and 2 deleterious missense variants
(p.G695D and p.G711E) that affect highly conserved residues
in the C-terminal noncollagenous 1 domain. The non-
collagenous 1 domain mediates proper folding of the protein
and the assembly of collagen VIII and X into polygonal
lattices.49e51 Therefore, these COL8A1 variants may lead to
an aberrantly folded protein, impairing transport of the protein
to Bruch’s membrane or altering Bruch’s membrane integrity
or stability. Consequently, this may contribute to the devel-
opment of early AMD. In our study, we observed a higher,
albeit nonsigniﬁcant, proportion of hyperpigmentary changes
in AMD patients carrying COL8A1 variants. Larger patient
populations are needed to validate this ﬁnding. Previous
studies have implicated COL8A1 in retinal angiogenesis by
mediating proliferation and migration of endothelial cells,437
Figure 4. Localization of Col8a1 in mouse retinas. A, The localization of Col8a1 (in red) was studied on P90 retinas derived from wild-type C57BL/6J mice.
Laminin b-1 (Lamb1; green) was used as a Bruch’s membrane marker. Col8a1 colocalizes with Lamb1 at Bruch’s membrane. Col8a1 staining also showed a
weaker signal in other layers of the retina. B, Magniﬁcations of the outer region of the retina, where the colocalization between Lamb1 and Col8a1 can be
appreciated. DAPI (40,6-diamidino-2-phenylindole) (blue) was used to stain cell nuclei. BM ¼ Bruch’s membrane; GCL ¼ ganglion cell layer; INL ¼ inner
nuclear layer; IPL ¼ inner plexiform layer; IS ¼ inner segment; ONL ¼ outer nuclear layer; OPL ¼ outer plexiform layer; OS ¼ outer segment; RPE ¼
retinal pigment epithelium.
Ophthalmology Volume -, Number -, Month 2018suggesting that COL8A1 variants could contribute to the
development of neovascularization in late AMD. In the
Rotterdam Study, we identiﬁed 3 COL8A1 carriers with GA,
but no carriers who demonstrated CNV (Table 2). However,
in the European Genetic Database cohort, we identiﬁed 1
carrier with GA, 3 carriers with CNV, and 2 carriers with
the mixed type of AMD with GA and CNV (data not
shown). Therefore, we cannot conclude that there is an
overrepresentation of CNV in carriers of COL8A1 variants.
Interestingly, COL8A1 variants seem to contribute to
refractive error, although the contribution to severe myopic
errors was insigniﬁcant. In the Rotterdam Study, the8refractive error is, on average, emmetropic in AMD patients
carrying COL8A1 variants. Therefore, it is unlikely that
myopic thinning of Bruch’s membrane contributed to the
development of AMD in these carriers.
The ﬁndings described herein need to be interpreted in
light of several strengths and limitations. We demonstrated
that WES with relatively large cohorts is an efﬁcient strategy
to detect rare variants in AMD-associated genes. Previous
studies that detected rare variants in AMD were focused on
predeﬁned gene sets using targeted sequencing12 or
predeﬁned variant sets using exome arrays,8 whereas our
study performed a comprehensive exome-wide search for
Corominas et al  WES in AMD Identiﬁes Variants in COL8A1rare variants using WES. The main advantage of performing
WES is that it enables the identiﬁcation of all rare variants
present in coding regions across the genome, allowing a
more comprehensive evaluation of rare variants than other
approaches based on a limited set of genes or variants. A
burden of rare variants has been described previously in
CFH, CFI, TIMP3, and SLC16A8,8,12 but these ﬁndings
were not conﬁrmed in our study. This may be because
although we had a relatively large cohort, our study may not
have had sufﬁcient power to detect these associations. In the
study by Fritsche et al,8 a larger cohort was used, consisting
of 16 144 AMD patients and 17 832 control participants.
However, most of the COL8A1 variants (11/14) identiﬁed
by WES in our study were not present on the exome array
that was used by Fritsche et al, which may explain why a
burden of rare COL8A1 variants was not observed in that
study.8 In addition, differences in study designs and
populations, case deﬁnition, geographical origin, statistical
tests used, or correction for confounding factors may
explain the different results observed among these studies.
In conclusion, we performed an exome-wide sequence
analysis of rare protein-altering variants in AMD and we
detected a burden of rare variants in the COL8A1 gene. A
common intergenic variant near this gene was associated pre-
viously with AMD risk,7,8 but no protein-altering variants
within the gene have been described in AMD so far. This work
supports a role for protein-altering variants in the COL8A1 gene
inAMDpathogenesis and suggests that the previously observed
association of the common intergenic variant is driven by effects
on COL8A1. In this study, we demonstrate the presence of
Col8a1 in Bruch’s membrane, further supporting the role of
COL8A1 variants in AMD pathogenesis. Protein-altering vari-
ants in COL8A1 may alter the integrity of Bruch’s membrane,
contributing to the accumulation of drusen and the development
of AMD. This study showed that WES provides a fruitful
approach for gene and variant identiﬁcation in complex disor-
ders such as AMD. Collaborative efforts among the scientiﬁc
community are needed to perform even larger exome- or
genome-wide sequencing studies52 that will increase our
understanding of the genetic architecture and disease
mechanisms of AMD further.
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